MedTrace Logo

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

NCT04052048 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-04-02

No results posted yet for this study

Summary

A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.

Conditions

  • Prostate Cancer Aggressiveness

Interventions

DIAGNOSTIC_TEST

Subtraction Normalized Expression of Phagocytes Blood Test

Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness

Sponsors & Collaborators

  • Immunis.AI

    lead INDUSTRY

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-09
Primary Completion
2026-11-15
Completion
2029-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04052048 on ClinicalTrials.gov